Metex Pen (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, preventing the formation of tetrahydrofolate needed for DNA synthesis. This limits the proliferation of rapidly dividing cells, including immune cells that drive inflammation and malignant cells, while also increasing extracellular adenosine that has anti‑inflammatory properties.

The dose of Metex Pen is individualized by the prescribing clinician based on the specific indication, disease severity, patient weight, renal and hepatic function, and response to therapy. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Methotrexate is classified as Pregnancy Category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be stopped well before conception. Breastfeeding is also not recommended, as methotrexate can be excreted in milk and affect the infant.

To request Metex Pen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and the necessary import documentation.

Metex Pen offers a pre‑filled subcutaneous delivery system, which can improve patient convenience and absorption compared with oral tablets that have variable bioavailability. Compared with biologic DMARDs, methotrexate is less costly but requires regular laboratory monitoring. Efficacy is comparable for many patients with rheumatoid arthritis, while safety profiles differ.

Metex Pen must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Keep the pen in its original packaging until use, and discard any product that has been exposed to temperatures outside this range.

Metex Pen is a pre‑filled pen designed for subcutaneous injection. After selecting the prescribed dose, the user or healthcare professional removes the safety cap, cleans the injection site, and presses the activation button to deliver the medication into the subcutaneous tissue, typically in the abdomen or thigh.

Serious risks include severe liver toxicity, pulmonary fibrosis, profound bone‑marrow suppression leading to pancytopenia, acute renal failure, life‑threatening infections, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they develop jaundice, persistent cough, unexplained fever, bleeding, or severe skin rash.

Metex Pen is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe renal or hepatic impairment, and those with existing bone‑marrow failure. Caution is also advised for patients with active infections, pulmonary disease, or those receiving other myelosuppressive agents.